Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.19), $0.43 worse than the analyst estimate of ($1.76). Revenue for the quarter came in at $79.9 million versus the consensus estimate of $83.65 million.

Cash balance of approximately $814 million as of March 31, 2022

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.